Come up with a name for your new list and we'll add to it:
Aeolus Pharmaceuticals raised a round of funding on July 07, 2003. Investors include
Xmark Asset Management.
Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a…